CBD is a great tool to help Alzheimer’s patients

140 0

The cannabis compound has the ability to control some Alzheimer’s symptoms

Alzheimer’s is a progressive neurodegenerative disease that usually occurs in adults over the age of 65. It causes dementia-like symptoms and as it progresses, it renders the sufferer increasingly unable to care for themselves. There is no cure for Alzheimer’s, but it has been shown that medicines such as cannabis and its star component, cannabidiol (CBD), can slow its progression.

Regular physical and mental exercise is believed to be of vital importance in maintaining neuronal health and is undoubtedly the healthiest and most effective method of achieving this. However, the balance of chemicals in the brain can also be improved by using certain exogenous compounds, such as those contained in cannabis. Cannabis contains several compounds, including CBD, which are structurally similar and have different effects on brain function and metabolism.

CBD can reduce inflammation, act as antioxidants and neuroprotectants, and even stimulate the growth of new neural tissue. So, if taken regularly, there is evidence that it will not only slow the progression of existing Alzheimer’s cases, but also delay the onset of new cases.

Oxidative stress and the release of reactive oxygen species is a key component of diseases such as Alzheimer’s and is intrinsically linked to immune inflammation. The role of the ECS system in modulating oxidative stress processes is not fully understood. However, it has been repeatedly shown that CBD administration can help reduce its effects and may provide a neuroprotective effect on neurons, slowing the rate of oxidative cell death.

In addition to reducing inflammation and mediating the effects of oxidative stress, CBD is also believed to promote the growth of new neural tissue. In Alzheimer’s disease patients, the rapid destruction of neural tissue causes devastating neurological effects. Additionally, and the normal processes of neurogenesis are disrupted by the presence of beta-amyloid. Therefore, developing therapies that can stimulate neurogenesis may delay the progression of the disease or even reverse the symptoms to some extent.